New PD-1 Immunotherapy Combinations Push The Envelope In Melanoma

Early data from small studies presented at the Society of Melanoma Research meeting suggest potential for safely and effectively combining PD-1 inhibitors with a range of drugs, including Amgen’s Imlygic vaccine.